MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • 2023 International Congress

    Transcriptome-microRNA correlation and the regulation of targeted gene expression in de novo Parkinson’s disease patients.

    KE. Choi, SY. Kim, J. Jang, I. Hwang, KW. Lee, JS. Kim (Seoul, Republic of Korea)

    Objective: To conduct a case-control study in single, comprehensive movement disorder center in Seoul. Background: Parkinson’s disease (PD) is the second most common neurodegenerative disease…
  • 2023 International Congress

    Proof-of-concept clinical trial: Prevent cognitive decline in GBA-associated Parkinson’s Disease

    K. Brockmann, JC. Corvol, A. Difonzo, S. Durrleman, T. Gasser, M. Hu, R. Krüger, I. Liepelt-Scarfone, M. Matarazzo, A. Pilotto, T. Simuni, P. Svenningsson, D. Weintraub, G. Pagano (Tuebingen, Germany)

    Objective: To prevent cognitive decline in GBA-associated Parkinson’s Disease (PD). Background: Dementia represents a key milestone in the course of PD with limited effective treatments…
  • 2023 International Congress

    Elevated plasma CREG1 levels are linked to a lower risk of Parkinson’s disease

    X. Guo, R. Zhou, G. Tian, R. Li (Xi'an, China)

    Objective: The purpose of this study is to assess the causal associations between plasma cellular repressor of E1A-stimulated genes 1 (CREG1) levels and the risk…
  • 2023 International Congress

    Cerebrospinal fluid biomarkers for diagnosis of Parkinson’s disease: a systematic review and network meta-analysis

    SM. Li, YC. Zheng, C. Yang, JY. Wu, ZW. Yu, Y. Jiang, T. Feng (Beijing, China)

    Objective: In this study, we intended to use network meta-analysis to compare the diagnostic performances of different CSF biomarkers in the diagnosis and differential diagnosis…
  • 2023 International Congress

    A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data

    T. Nikolcheva, G. Pagano, N. Pross, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, K. Seppi, A. Monnet, N. Shariati, L. Rutten-Jacobs, S. Zanigni, T. Kustermann, K. Taylor, D. Trundell, H. Svoboda, A. Bonni, P. Fontoura, R. Doody (BASEL, Switzerland)

    Objective: The study will evaluate the efficacy and safety of prasinezumab in individuals with early-stage Parkinson's disease (PD) on stable symptomatic therapy. Background: Available treatments…
  • 2023 International Congress

    Analysis of the network of genes related to Parkinson’s and identification of key proteins

    H. Ghapani, D. Morshedi, S. Parsafar, F. Aliakbari (Tehran, Islamic Republic of Iran)

    Objective: Parkinson's disease (PD) is one of the increasing age-related diseases with no definite treatment. PD is considered as a disorder with genetic and non-genetic…
  • 2023 International Congress

    Neuroprotective effects of oral consumption of Bifidobacterium lactis and Lactobacillus acidophilus probiotics on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropytide-induced Parkinson’s Disease mouse model

    C. Mo, Y. Qian, Y. Zhang, X. He, Y. Lai, S. Xu, P. Ai, X. Yang, Q. Xiao (Shanghai, China)

    Objective: To explore the effects of probiotics strains Bifidobacterium animalis subsp. lactis (B.lactis) and Lactobacillus acidophilus (L.acidophilus) on the inflammation of gut-brain axis and degeneration…
  • 2023 International Congress

    Salivary α-synuclein in Parkinson’s disease – a pilot study

    M. Kaiserova, D. Hrabos, M. Levkova, M. Kavalkova, R. Kopacik, K. Mensikova, P. Kanovsky (Olomouc, Czech Republic)

    Objective: The aim of our study was to measure total salivary α-synuclein in Parkinson´s disease (PD) patients to assess its potential as a biomarker of…
  • 2023 International Congress

    A human tissue engineered nigrostriatal system as a testbed for understanding PD pathophysiology and therapeutic development

    D. Chouhan, K. Browne, R. Patel, S. Karandikar, F. Laimo, D. Cullen, J. Duda (Philadelphia, USA)

    Objective: The objective of these studies is to develop a tissue engineered nigrostriatal system involving human dopaminergic and striatal cells to recapitulate many of the…
  • 2023 International Congress

    The Synuclein-One Study: Detection of Cutaneous Phosphorylated alpha-synuclein for the Diagnosis of the Synucleinopathies

    R. Freeman, T. Levine, J. Stohl, B. Bellaire, C. Gibbons (BOSTON, USA)

    Objective: The Synuclein-One study is an NIH-funded 30-site, multicenter trial of 428 patients with synucleinopathies  including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 60
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley